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DepressionAbstract Objectives: Chronic lung diseases lead to impairment of daily activities, work and qual-
ity of life. The aim of this work was to assess the quality of life, depression and anxiety in Egyptian
patients with chronic lung diseases.
Patients and methods: This study was conducted on 117 patients with chronic lung disease.
Patients had chronic obstructive lung disease (48), idiopathic pulmonary ﬁbrosis (36) or bronchiec-
tasis (33). All patients were subjected to history taking, clinical examination, spirometry, arterial
oxygen saturation and 6-min walk distance test. All patients responded to the modiﬁed Medical
Research Council (MRC) dyspnea scale, Speciﬁc Activity Scale (SAS), Hamilton Anxiety Rating
Scale (HAMA), Hamilton Depression Rating Scale (HAMD) and Saint George Respiratory Ques-
tionnaire (SGRQ).
Results: The majority of patients had an anxiety or depression disorder or both. The SGRQ
score showed a signiﬁcant direct correlation with age, disease onset, MRC, the SAS, the HAMA
and the HAMD scores. Linear regression analysis showed that body mass index, MRC, SAS
and HAMD were found to be signiﬁcant predictors for the total score of the SGRQ. None of
the spirometry parameters or the arterial oxygen saturation were found to be signiﬁcant predictors
of the quality of life.
Conclusion: In chronic lung diseases, depression and anxiety disorders are not uncommon.
SGRQ is a valid measure for quality of life in such patients that appears to be sensitive in
732 T.S. Morsi et al.distinguishing different levels of health impairment in such patients. Body mass index, MRC, SAS
and HAMD were found to be independent predictors for SGRQ score.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic lung diseases lead to impairment of daily activities,
work and quality of life. The presence of depression and anx-
iety, which was reported to be associated with such diseases,
could only increase the deterioration in social functioning
and quality of life of such patients [1]. The World Health Orga-
nization deﬁned quality of life as individuals’ perception of
their position in life in the context of the culture and value sys-
tems in which they live and in relation to their goals, expecta-
tions, standards and concerns [2]. Health-related quality of life
(HRQL) is the quality of life relative to one’s health or disease
status, which is a concern of policymakers, researchers, and
health care practitioners [3]. Health-related quality of life
(HRQL) questionnaires allow for direct measurements of the
impact of the disease on patient’s daily life. Such question-
naires can also be valuable in the assessment of the beneﬁts
and side effects of different therapeutic measures. The in-
creased appreciation of the signiﬁcance of understanding and
measuring the quality of life in chronic respiratory diseases
has led to development of quite numerous health related qual-
ity of life questionnaires [4]. The Saint George’s Respiratory
Questionnaire (SGRQ), although originally designed to assess
the quality of life in COPD patients, has proven efﬁcient also
in the assessment of other chronic lung diseases such as bron-
chiectasis and interstitial lung diseases [4,5].
The prevalence of anxiety and depression in chronic lung
diseases is not uncommon [1]. There is increasing evidence sug-
gesting that depression and anxiety might have a direct impact
on health rather than being mere consequences or markers of
disease severity [6]. Anxiety and depression, although poten-
tially modiﬁable, are signiﬁcant comorbid conditions in
chronic lung diseases [7].
The aim of this work was to assess the quality of life,
depression and anxiety in Egyptian patients with chronic lung
diseases and their correlation with the clinical and physiologi-
cal status of the patients.Patients and methods
The study was approved by Alexandria University Ethics
Committee and a written informed consent was obtained from
all patients included in the study. The patients were recruited
from the Chest department of the main teaching hospital of
Alexandria University, Egypt. The study population included
117 patients with clinically stable chronic lung disease. There
were 48 patients with chronic obstructive lung disease
(COPD), 36 patients with idiopathic pulmonary ﬁbrosis
(IPF) and 33 patients with bronchiectasis. Patients who had
experienced acute exacerbations in their underlying chronic
lung disease in the past month were excluded. All patients were
subjected to full history taking and complete clinical examina-
tion. The patients breathlessness was assessed using the modi-
ﬁed Medical Research Council (MRC) dyspnea scale [8].Spirometry was performed in the pulmonary function labo-
ratory using Chestgraph HI-701 (version 1). The American
Thoracic Society and European Respiratory Society guide-
lines’ standards were followed [9,10]. Patients were tested in
the sitting position. Each patient performed at least three
acceptable forced expiratory maneuvers, which fulﬁlled the cri-
teria of repeatability. Measurements included forced vital
capacity (FVC), forced expiratory volume in the ﬁrst second
(FEV1), ratio of FEV1 to FVC (FEV1/FVC), forced expiratory
ﬂow during the middle portion of forced expiration (FEF
25–75%) and forced expiratory time (FET). Finally, arterial
oxygen saturation (SpO2) of hemoglobin was measured using
pulse oximetry.
All patients answered to the Speciﬁc Activity Scale (SAS)
questionnaire [11]. It is formed of series of pre-established pre-
cise questions which are based on increasingly intense exertion.
The questions are reﬁned through the interview to limit the de-
gree of subjectivity. The degree of functional impairment is
estimated using examples of exertion in daily living which
are picked out because they are varied and grouped according
to the quantity of energy required. The patients are then clas-
siﬁed according to severity into four classes from I to IV, IV
being the severest.
The Hamilton Anxiety Rating Scale (HAMA) [12] which is
a psychological questionnaire used by clinicians to rate the
severity of a patient’s anxiety was administered to all patients.
It is a questionnaire of 14 symptom-oriented questions. Each
of these symptoms is given a severity rating, from not present
(scored as 0), mild degree (scored as 1), moderate degree
(scored as 2), severe degree (scored as 3) to very severe degree
(scored as 4). The clinician must choose the possible responses
to each question by interviewing the patient and by observing
the patient’s symptoms. The total anxiety score ranges from 0
to 56, while a score from 8 to 14 denotes mild anxiety, 15–23
moderate anxiety and P24 denotes severe anxiety [13].
All patients were evaluated then by Hamilton Depression
Rating Scale (HAMD) [14]. This latter is a scale to determine
the patient’s level of depression. It has a list of 21 symptom-
oriented questions. The scoring is based on the ﬁrst 17 ques-
tions only. Nine of the items are scored on a ﬁve-point scale,
ranging from zero to four. A score of zero represents an ab-
sence of the depressive symptom being measured, a score of
one indicates doubt concerning the presence of the symptom,
a score of two indicates mild symptoms, a score of three indi-
cates moderate symptoms, and a score of four represents the
presence of severe symptoms. The remaining eight items are
scored on a three-point scale, from zero to two, with zero rep-
resenting absence of symptom, one indicating doubt that the
symptom is present, and two representing clear presence of
symptoms. Based on the total score, a score of 0–7 indicates
no depression, 8–16 mild depression, 17–23 moderate depres-
sion and P24 severe depression [15].
The HRQL of all patients was then evaluated using the
SGRQ [16]. The SGRQ is a standardized quality of life assess-
ment tool which consists of 76 items divided into three parts
Quality of life in with chronic lung diseases 733such as measuring symptoms, activity limitation and social and
emotional impact of disease. The Symptom component con-
tains items concerned with the level of symptomatology,
including frequency of cough, sputum production, wheeze,
breathlessness, and the duration and frequency of breathless-
ness or wheeze. The Activity component is concerned with
physical activities that either cause or are limited by breathless-
ness. The Impact component covers such factors as employ-
ment, being in control of health, panic, stigmatization, the
need for medication and its side effects, expectations for health
and disturbance of daily life. SGRQ scores were calculated
using score calculation algorithms and missing data imputa-
tion (if total number of missing items was <10). For each
component and for the overall total questionnaire scores are
calculated. The scores are then transformed into percentage
of maximum possible scores, ranging from zero (no impair-
ment) to 100 (maximum impairment). Thus, a higher score
means a poorer quality of life.
All patients completed a 6-min walk distance (6MWD) test
[17]. The test was performed according to the American tho-
racic society guidelines. The test was performed along a mea-
sured indoor corridor in our institute and participants were
encouraged to cover as much distance as possible. Oxygen sat-
uration was monitored during the procedure and oxygen was
provided to the patients whose oxygen saturation decreased
below 85%.
Handling and analysis of data
Data were analyzed using SPSS system ﬁles (SPSS package
version 18). Descriptive statistics including frequency, distribu-
tion, mean and standard deviation were used to describe differ-
ent characteristics. Kolmogorov–Smirnov test was used to
examine the normality of data distribution. Univariate analy-
ses including: ANOVA test and Kruskal Wallis test were used
to test the signiﬁcance of results of quantitative variables.Table 1 Personal, clinical and lung functional characteristics of the
COPD (n= 48) (1) IPF (n= 36) (2) Br
Age (years) 66.8 ± 7.8 53.0 ± 13.9 42
Gender M: 45 (93.8%) M: 8 (22.2%) M
BMI (kg/m2) 21.9 ± 6.5 27.4 ± 7.1 21
Disease onset (years) 11.8 ± 9.1 7.9 ± 5.4 16
MRC
1 4 (8.3%) 0 (0%) 3 (
2 0 (0%) 12 (33.3%) 12
3 9 (18.8%) 8 (22.2%) 9 (
4 35 (72.9%) 16 (44.5%) 9 (
FVC% of pred 45.0 ± 12.7 46.3 ± 14.0 39
FEV1% of pred 33.4 ± 14.2 54.0 ± 20.0 32
FEV1/FVC 51.5 ± 12.7 84.5 ± 9.7 66
FEF25–75%% of pred 28.3 ± 20.9 76.7 ± 33.7 31
FET (seconds) 5.8 ± 1.9 2.8 ± 0.9 4.5
SpO2 (%) 94.1 ± 4.1 89.5 ± 8.9 93
COPD: chronic obstructive lung disease; IPF: idiopathic pulmonary ﬁbros
vital capacity; FEV1: forced expiratory volume in the ﬁrst second; FEF:
SpO2: arterial oxygen saturation modiﬁed; MRC: Medical Research Cou
X2: Chi-square test; F: ANOVA test; KWX2: Kruskal–Wallis test; MCP: M
* Signiﬁcant at P 6 0.05.Chi-Square test and Monte Carlo test were used to test the sig-
niﬁcance of results of qualitative variables. Tamhane and Bon-
ferroni Post Hoc tests were used to detect differences in-
between the studied groups. Linear correlation using Spear-
man Rho correlation coefﬁcient was conducted to show corre-
lation between studied scores and characteristics of patients
groups. Linear regression was conducted to reveal the predic-
tors of St George score among different groups of patients.
The signiﬁcance of the results was at the 5% level of
signiﬁcance.
Results
The studied patients’ personal and clinical characteristics are
shown in Table 1. The age of the patients was signiﬁcantly
higher in the COPD group than the other two groups, being
also higher in the interstitial ﬁbrosis group than the bronchiec-
tasis one. There was a signiﬁcantly higher number of males in
the COPD group than the other two groups. The body mass
index of the idiopathic pulmonary ﬁbrosis was signiﬁcantly
higher than that of the COPD and that of the bronchiectasis
group. The disease onset in years was signiﬁcantly shorter in
the idiopathic pulmonary ﬁbrosis group. Cough was present
in all bronchiectasis and interstitial ﬁbrosis patients and in
the majority of patients with COPD. Haemoptysis was present
only in 18 (54.5%) of bronchiectasis patients. There was signif-
icant difference between the MRC dyspnea scale of all three
groups of patients.
Regarding the spirometry parameters, the FVC percent of
predicted value did not show signiﬁcant differences between
the three groups of the studied patients. The FEV1 percent
of predicted value of the IPF group was signiﬁcantly higher
than the other two groups. The FEV1/FVC was signiﬁcantly
different between the three groups of patients, being lowest
in the COPD group followed by the bronchiectasis and highest
in the ﬁbrosis group. The FEF25–75% percent of predicted valuestudied patients.
(n= 33) (3) Signiﬁcance Post-hoc test
.9 ± 11.5 F= 47.38, P< 0.0001* (1,2)* (1,3)* (2,3)*
: 15 (45.5%) X2 = 46.269, P< 0.0001*
.6 ± 4.2 KWX2 = 23.88, P< 0.0001* (1,2)* (2,3)*
.5 ± 9.3 KWX2 = 16.668, P< 0.0001* (2,3)*
9.1%) MCP< 0.0001*
(36.3%)
27.3%)
27.3%)
.0 ± 17.1 F= 2.551, P= 0.082
.9 ± 16.6 F= 19.049, P< 0.0001* (1,2)* (2,3)*
.9 ± 17.2 F= 63.011, P< 0.0001* (1,2)* (1,3)* (2,3)*
.1 ± 17.8 KWX2 = 35.378, P< 0.0001* (1,2)* (2,3)*
± 1.9 KWX2 = 48.752, P< 0.0001* (1,2)* (1,3)* (2,3)*
.5 ± 4.9 KWX2 = 10.109, P= 0.006* (1,2)*
is; Br: bronchiectasis; n: number; BMI: body mass index; FVC: forced
forced expiratory ﬂow; FET: forced expiratory time; pred: predicted;
ncil dyspnea scale.
onte Carlo test.
Table 2 Functional performance, anxiety, depression and quality of life of the studied patients.
COPD (n= 48) (1) IPF (n= 36) (2) Br (n= 33) (3) Signiﬁcance Post-hoc test
SAS 3.8 ± 0.7 3.2 ± 0.9 2.8 ± 0.9 KWX2 = 24.47, P< 0.0001* (1,2)* (1,3)*
6MWD (m) 216.6 ± 72.2 143.3 ± 66.8 180.5 ± 74.2 F= 10.973, P< 0.0001* (1,2)*
HAMA 10.9 ± 5.7 12.8 ± 5.3 10.5 ± 3.0 F= 2.207, P= 0.115
HAMD 14.6 ± 4.8 14.6 ± 6.1 12.0 ± 4.2 F= 3.098, P= 0.049* (1,3)* (2,3)*
SGRQ (%)
S 71.4 ± 6.1 62.2 ± 5.9 75.7 ± 6.9 F= 6.328, P= 0.002* (1,2)* (2,3)*
A 86.4 ± 17.7 73.1 ± 25.9 62.1 ± 23.0 KWX2 = 27.148, P< 0.0001* (1,2)* (1,3)*
I 55.2 ± 15.5 58.2 ± 23.3 54.9 ± 13.7 F= 4.357, P= 0.015* (1,3)*
T 73.2 ± 15.1 63.4 ± 21.5 60.5 ± 14.2 KWX2 = 16.747, P< 0.0001* (1,2)* (1,3)*
COPD: chronic obstructive lung disease; IPF: idiopathic pulmonary ﬁbrosis; Br: bronchiectasis; n: number; SAS: speciﬁc activity scale; 6MWD:
6-min walk distance; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale; SGRQ: Saint George’s Respiratory
Questionnaire; S: symptoms score; A: activity score; I: impact score; T: total score.
KWX2: Kruskal–Wallis test; F: ANOVA test.
* Signiﬁcant at P 6 0.05.
734 T.S. Morsi et al.was signiﬁcant higher in the idiopathic pulmonary ﬁbrosis
group than the other two groups. The FET was signiﬁcantly
different between the three groups of patients, being shortest
in the IPF group, followed by the bronchiectasis one and lon-
gest in the COPD group. The arterial oxygen saturation
showed only signiﬁcant difference between the COPD and idi-
opathic pulmonary ﬁbrosis groups being lower in the latter
one.
The functional performance, psychological proﬁle and
quality of life results for the three studied groups are shown
in Table 2. The SAS was signiﬁcantly higher in the COPD
group than the other two groups. The 6MWDwas signiﬁcantly
higher in the COPD group than the IPF one. Overall, the
HAMA scale did not show signiﬁcant differences between
the three studied groups. In the COPD group, 20 (41.6%) pa-
tients did not have anxiety disorder while 28 (58.3%) had an
anxiety disorder which was mild in 21 (43.75%) patients, mod-
erate in 5 (10.4%) patients and severe in 2 (4.2%) patients. In
the IPF, 12 (33.3%) patients did not have any anxiety disor-
ders while 24 (66.6%) patients had an anxiety disorder which
was mild in 18 (50%) patients and moderate in 6 (16.6%) pa-
tients. In the bronchiectasis group, 13 (39.3%) patients did not
have anxiety disorder while 20 (60.6%) patients had an anxiety
disorder all of them being mild. The HAMD scale was signif-
icantly lower in the bronchiectasis group than the other two
groups. In the COPD group, 19 (39.5%) patients did not have
a depression disorder while 29 (60.4%) had a depression disor-
der which was mild in 19 (39.5%) patients and moderate in 10
(20.8%) patients. In the IPF group, 14 (38.8%) patients did
not have a depression disorder while 22 (61.1%) had a depres-
sion disorder which was mild in 11 (30.5%) patients and mod-
erate in 11 (30.5%) patients. In the bronchiectasis group, 16
(48.4%) patients did not have a depression disorder while 17
(51.5%) patients had a depression disorder which was mild
in 15 (45.45%) patients and moderate in 2 (6.06%) patients.
The SGRQ symptoms component percent in COPD ranged
from 40.8% to 92.3%, in IPF from 42.4% to 95.2% and in
bronchiectasis from 35.2% to 92.8%. The activity component
of the SGRQ in COPD ranged from 29.2% to 92.5%, in IPF
from 23.3% to 92.5% and in bronchiectasis from 23.1% to
92.5%. The impact component of the SGRQ in COPD ranged
from 24.5% to 85.4%, in IPF from 11.6% to 86.6% and in
bronchiectasis from 25.9% to 72.2%. The overall total SGRQscore in COPD ranged from 28.6% to 87.8%, in IPF from
21.9% to 89.8% and in bronchiectasis from 28.4% to
79.4%. The SGRQ total score was signiﬁcantly higher in
COPD patients than the other two groups.
The correlations of the HAMA score with other patients’
parameters are shown in Table 3. In the COPD group of pa-
tients, it showed a signiﬁcant inverse correlation with patients’
age and a signiﬁcant direct one with the SAS. In the IPF
group, it showed a signiﬁcant direct correlation with the
MRC and the SAS. In the bronchiectasis group, it showed a
signiﬁcant direct correlation with the arterial oxygen satura-
tion. Overall in all the patients, the HAMA score showed a sig-
niﬁcant inverse correlation with the age and a signiﬁcant direct
correlation with the SAS.
The correlations of the HAMD score with other patients’
parameters are shown in Table 4. In the COPD group of pa-
tients, it showed a signiﬁcant direct correlation with the SAS
and the HAMA. The score was signiﬁcantly higher in the fe-
male population compared to the male one. In the IPF group,
it showed a signiﬁcant direct correlation with the BMI, the dis-
ease onset, the MRC, the SAS and the HAMA. In the bronchi-
ectasis group, it showed a signiﬁcant inverse correlation with
the BMI, the onset of the disease the arterial oxygen saturation
and the HAMA. The score was signiﬁcantly higher in the fe-
male population compared to the male one. Overall in all the
patients, the HAMD score showed a signiﬁcant direct correla-
tion with the MRC, the SAS and the HAMA.
The correlations of the SGRQ score are shown in Table 5.
In the COPD group of patients, it showed a signiﬁcant
inverse correlation with the age, the FEV1 and the 6MWD;
while it showed a signiﬁcant direct correlation with the dis-
ease onset, the MRC and the SAS. The male patients had
a signiﬁcant higher score than the female ones. In the IPF
group of patients, it showed a signiﬁcant direct correlation
with the BMI, the MRC, the SAS, the HAMA and the
HAMD. In the bronchiectasis group, it showed a signiﬁcant
direct correlation with the MRC, the SAS and the HAMA.
The male patients had a signiﬁcant higher score than the
female ones. Overall, in all the patients, the SGRQ score
showed a signiﬁcant direct correlation with age, disease onset,
MRC, the SAS, the HAMA and the HAMD scores. Overall,
the male patients had a signiﬁcant higher score than the
female ones.
Table 3 Correlations of Hamilton Anxiety Rating Scale in the different studied groups.
HAMA
COPD (n= 48) IPF (n= 36) Br (n= 33) T (n= 117)
r P r P r P r P
Gender 0.188 0.202 0.162 0.345 0.117 0.515 0.076 0.415
Age 0.323 0.025* 0.091 0.597 0.32 0.069 0.197 0.033*
BMI 0.212 0.147 0.243 0.153 0.58 0.747 0.037 0.693
DO 0.055 0.71 0.316 0.06 0.109 0.547 0.106 0.253
MRC 0.074 0.617 0.381 0.022* 0.077 0.67 0.168 0.07
FVC 0.119 0.421 0.26 0.126 0.154 0.393 0.075 0.424
FEV1 0.254 0.081 0.198 0.247 0.015 0.932 0.037 0.689
SpO2 0.022 0.884 0.201 0.24 0.628 0.0001* 0.146 0.116
SAS 0.335 0.02* 0.535 0.001* 0.094 0.603 0.298 0.001*
6MWD 0.124 0.401 0.095 0.58 0.055 0.76 0.081 0.385
COPD: chronic obstructive lung disease; IPF: idiopathic pulmonary ﬁbrosis; Br: bronchiectasis; T: total number of patients; n: number; BMI:
body mass index; DO: disease onset; MRC: Medical Research Council dyspnea scale; FVC: forced vital capacity; FEV1: forced expiratory
volume in the ﬁrst second; SpO2: arterial oxygen saturation, SAS: speciﬁc activity scale; 6MWD: 6-min walk distance; HAMA: Hamilton
Anxiety Rating Scale.
r: Pearson coefﬁcient.
* Signiﬁcant at P 6 0.05.
Table 4 Correlations of Hamilton Depression Rating Scale in the different studied groups.
HAMD
COPD (n= 48) IPF (n= 36) Br (n= 33) T (n= 117)
r P r P r P r P
Gender 0.356 0.013* 0.156 0.364 0.35 0.046* 0.163 0.08
Age 0.133 0.369 0.088 0.611 0.042 0.818 0.095 0.307
BMI 0.027 0.853 0.365 0.029* 0.569 0.001* 0.007 0.94
DO 0.158 0.284 0.456 0.005* 0.54 0.001* 0.074 0.426
MRC 0.046 0.755 0.716 0.0001* 0.101 0.578 0.411 0.0001*
FVC 0.026 0.861 0.133 0.439 0.009 0.96 0.024 0.797
FEV1 0.01 0.945 0.081 0.637 0.024 0.893 0.066 0.48
SpO2 0.27 0.063 0.068 0.695 0.686 0.0001* 0.031 0.743
SAS 0.458 0.001* 0.739 0.0001* 0.297 0.093 0.553 0.0001*
6MWD 0.148 0.316 0.239 0.161 0.22 0.219 0.053 0.568
HAMA 0.697 0.0001* 0.839 0.0001* 0.396 0.022* 0.681 0.0001*
COPD: chronic obstructive lung disease; IPF: idiopathic pulmonary ﬁbrosis; Br: bronchiectasis; T: total number of patients; n: number; BMI:
body mass index; DO: disease onset; MRC: Medical Research Council dyspnea scale; FVC: forced vital capacity; FEV1: forced expiratory
volume in the ﬁrst second; SpO2: arterial oxygen saturation, SAS: speciﬁc activity scale; 6MWD: 6-min walk distance; HAMA: Hamilton
Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale.
r: Pearson coefﬁcient.
* P signiﬁcant at 6 0.05.
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with different studied parameters are shown separately in Ta-
ble 6. The symptom and activity components scores were sig-
niﬁcantly higher in males than in females. The symptom
component showed a signiﬁcant direct correlation with the dis-
ease onset, dyspnea severity, oxygen saturation, SAS, HAMA
and HAMD. It showed a signiﬁcant inverse correlation with
the FEV1. The activity component showed a signiﬁcant direct
correlation with age, disease onset, SAS, HAMA and HAMD.
It showed a signiﬁcant inverse correlation with FVC and
FEV1. The impact component showed a signiﬁcant direct cor-
relation with age, dyspnea severity, SAS, HAMA and HAMD.
The linear regression analysis for predictors of the SGRQ
among the three studied groups and amongst all studied pa-tients is shown in Table 7a–d. Amongst all studied patients,
the BMI, dyspnea severity, SAS and HAMD were found to
be signiﬁcant predictors for the total score of the SGRQ. None
of the spirometry parameters nor the arterial oxygen satura-
tion were found to be signiﬁcant predictors of the quality of
life. In the COPD group, age, BMI, disease onset, dyspnea
severity, FVC, FEV1/FVC, FET, HAMD and 6MWD were
found to be signiﬁcant predictors for the SGRQ score. In the
IPF group, age, FVC, FEV1/FVC, SAS and HAMA were
found to be signiﬁcant predictors for the SGRQ score. In the
bronchiectasis group, age, BMI, disease onset, dyspnea sever-
ity, FEV1, arterial oxygen saturation, SAS, HAMD, HAMA
and 6MWD were found to be signiﬁcant predictors for the
SGRQ score (Figs. 1–8).
Table 5 Correlations of Saint George’s Respiratory Questionnaire in the different studied groups.
SGRQ
COPD (n= 48) IPF (n= 36) Br (n= 33) T (n= 117)
r P r P r P r P
Gender 0.345 0.016* 0.311 0.065 0.577 0.0001* 0.258 0.005*
Age 0.352 0.014* 0.167 0.33 0.274 0.123 0.303 0.001*
BMI 0.242 0.098 0.338 0.044* 0.138 0.445 0.044 0.639
DO 0.655 0.0001* 0.263 0.121 0.219 0.221 0.29 0.002*
MRC 0.779 0.0001* 0.775 0.0001* 0.659 0.0001* 0.805 0.0001*
FVC 0.056 0.704 0.0 1.0 0.005 0.978 0.034 0.715
FEV1 0.408 0.004* 0.016 0.926 0.17 0.343 0.087 0.351
SpO2 0.277 0.057 0.164 0.34 0.251 0.16 0.084 0.368
SAS 0.544 0.0001* 0.894 0.0001* 0.74 0.0001* 0.817 0.0001*
6MWD 0.343 0.017* 0.325 0.053 0.073 0.688 0.115 0.215
HAMA 0.091 0.539 0.757 0.0001* 0.508 0.003* 0.418 0.0001*
HAMD 0.043 0.77 0.812 0.0001* 0.312 0.077 0.555 0.0001*
COPD: chronic obstructive lung disease; IPF: idiopathic pulmonary ﬁbrosis; Br: bronchiectasis; T: total number of patients; n: number; BMI:
body mass index; DO: disease onset; MRC: Medical Research Council dyspnea scale; FVC: forced vital capacity; FEV1: forced expiratory
volume in the ﬁrst second; FEF: forced expiratory ﬂow; SpO2: arterial oxygen saturation SAS: speciﬁc activity scale; 6MWD: 6-min walk
distance; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale; SGRQ: Saint George’s Respiratory
Questionnaire.
r: Pearson coefﬁcient.
* Signiﬁcant at P 6 0.05.
Table 6 Correlations of Saint George’s Respiratory Questionnaire three components with different studied parameters.
Symptom Activity Impact
r P r P r P
Gender 0.324* <0.001 0.277* 0.002 0.163 0.079
Age 0.022 0.816 0.429* <0.001 0.775* 0.003
DO 0.514* <0.001 0.060 0.521 0.164 0.078
MRC 0.452* <0.001 0.918* <0.001 0.703* <0.001
FVC 0.100 0.285 0.222* 0.016 0.120 0.199
FEV1 0.255* 0.005 0.270* 0.003 0.154 0.097
SpO2 0.239
* 0.009 0.088 0.344 0.102 0.272
SAS 0.396* <0.001 0.962* <0.001 0.728* <0.001
6MWD 0.053 0.572 0.119 0.200 0.119 0.203
HAMA 0.451* <0.001 0.374* <0.001 0.510* <0.001
HAMD 0.312* 0.001 0.607* <0.001 0.680* <0.001
DO: disease onset; MRC: Medical Research Council dyspnea scale; FVC: forced vital capacity; FEV1: forced expiratory volume in the ﬁrst
second; SpO2: arterial oxygen saturation, SAS: speciﬁc activity scale; 6MWD: 6-min walk distance; HAMA: Hamilton Anxiety Rating Scale;
HAMD: Hamilton Depression Rating Scale.
r: Pearson coefﬁcient.
* Signiﬁcant at P 6 0.05.
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Chronic lung diseases are common disorders. They are esti-
mated to occur in 10% of adults in the United States [18]. These
conditions impair daily living activities, social functioning and
psychological performance. Patients with chronic lung diseases
often experience depression and anxiety [19]; the presence of
those latter complicates the emotional and physical effects of
the disease. In the present study, most of our patients with
chronic lung disease had an anxiety or a depression disorder
or both. A large majority of these affections were mild. We used
the Hamilton Anxiety Scale to measure the degree of anxiety of
our patients. The HAMA although was developed four decades
ago, is still the most used internationally clinician-rated scale inclinical anxiety states [20]. In a comprehensive content analysis
of the items included in 27 different rating scales or question-
naires designed for anxiety, de Bonis concluded that the
HAMA appeared to cover the clinically most representative
items for states of anxiety [21]. It has obtained a status as the
international standard for measurement of anxiety [20].
In our study, 61.5% of all our patients had an anxiety dis-
order. These observations were higher than most previously re-
ported results which ranged widely from as low as thirteen
percent to percentages comparable to ours [22–25]; and were
higher in patients with other medical conditions [26]. Porzelius
and colleagues [27] found that 37% of patients with chronic
lung diseases stated that they had anxiety attacks. Dowson
et al. found anxiety in 50% of 72 patients with COPD
Table 7 Linear regression analysis for predictors of Saint George’s Respiratory Questionnaire.
Variables B SE t P
(a) Among all the studied cases
Age 0.016 0.094 0.171 0.864
BMI 5.634 2.189 2.574 0.012*
DO 0.231 0.123 1.876 0.064
MRC 7.763 2.744 2.830 0.006*
FVC 0.043 0.261 0.166 0.868
FEV1 0.059 0.282 0.211 0.834
FEV1/FVC 0.166 0.182 0.910 0.365
FEF25–75% 0.044 0.058 0.758 0.450
FET 1.076 0.687 1.565 0.121
SpO2 0.085 0.179 0.475 0.636
SAS 6.623 3.295 2.010 0.047*
HAMD 0.551 0.260 2.120 0.036*
HAMA 0.324 0.277 1.168 0.246
6MWD 0.016 0.016 1.029 0.306
Constant 290.040 106.71 2.718 0.008*
(Regression model: Adjusted R2 = 0.814; F= 32.654; P< 0.0001)
(b) Among COPD cases
Age 0.714 0.159 4.492 <0.0001*
BMI 3.723 1.564 2.380 0.023*
DO 0.559 0.141 3.960 <0.0001*
MRC 24.650 3.263 7.555 <0.0001*
FVC 0.321 0.085 3.763 0.001*
FEV1/FVC 0.384 0.174 2.209 0.034
*
FET 1.685 0.756 2.229 0.032*
SAS 7.254 3.671 1.976 0.056
HAMD 0.653 0.278 2.348 0.025*
HAMA 0.278 0.197 1.411 0.167
6MWD 0.111 0.026 4.349 <0.0001*
Constant 60.830 20.646 2.946 0.006*
(Regression model: Adjusted R2 = 0.936; F= 58.006; P< 0.0001)
(c) Among IPF cases
Age 0.240 0.042 5.763 <0.0001*
BMI 0.126 0.077 1.634 0.117
DO 0.019 0.031 0.605 0.552
MRC 0.332 2.286 0.145 0.886
FVC 0.138 0.058 2.376 0.027*
FEV1/FVC 1.236 0.050 24.970 <0.0001
*
FEF25–75% 0.019 0.012 1.524 0.142
FET 0.462 0.338 1.367 0.186
SpO2 0.038 0.025 1.541 0.138
SAS 13.718 2.322 5.908 <0.0001*
HAMD 0.287 0.230 1.246 0.227
HAMA 0.720 0.269 2.674 0.014*
6MWD 0.018 0.018 1.035 0.313
Constant 94.540 12.12 7.799 <0.0001*
(Regression model: Adjusted R2 = 1.0; F= 9126.445; P< 0.0001)
(d) Among bronchiectasis cases
Age 0.167 0.062 2.684 0.016*
BMI 1.595 0.359 4.440 <0.0001*
DO 0.484 0.070 6.904 <0.0001*
MRC 13.575 2.857 4.752 <0.0001*
FVC 0.056 0.075 0.745 0.467
FEV1 0.136 0.051 2.683 0.016*
FEV1/FVC 0.001 0.060 0.017 0.986
FEF25–75% 0.030 0.030 1.030 0.318
FET 0.273 0.294 0.930 0.366
SpO2 0.501 0.226 2.219 0.041
*
SAS 24.181 2.971 8.138 <0.0001*
HAMD 0.319 0.147 2.162 0.046*
(continued on next page )
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Table 7 (continued)
Variables B SE t P
HAMA 0.824 0.274 3.005 0.008*
6 MWD 0.099 0.011 9.056 <0.0001*
Constant 157.415 32.67 4.817 <0.0001*
(Regression model: Adjusted R2 = 0.999; F= 2849.88; P< 0.0001)
BMI: body mass index; DO: disease onset; MRC: Medical Research Council dyspnea scale; FVC: forced vital capacity; FEV1: forced expiratory
volume in the ﬁrst second; FEF: forced expiratory ﬂow; FET: forced expiratory time; SpO2: arterial oxygen saturation SAS: speciﬁc activity
scale; 6MWD: 6-min walk distance; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale.
* Signiﬁcant at P 6 0.05.
Fig. 1 Box plot of Hamilton Anxiety Scale among studied
patients.
Fig. 2 Box plot of Hamilton Depression Scale among studied
patients.
Fig. 3 Box plot of Saint George Respiratory Questionnaire
among studied patients.
Fig. 4 Box plot of Saint George Respiratory Questionnaire
components among studied patients.
738 T.S. Morsi et al.hospitalized for cardiorespiratory rehabilitation [28]. However,
Kunik and colleagues reported that 75% of 1334 patients
with chronic lung diseases screened positive for an anxiety
disorder. Fifty-two percent of those patients completed thepsychological evaluation and 80% of them were actually found
to have a clinically signiﬁcant level of anxiety. Moreover, 52%
of those latter had a severe level of anxiety [1]. This percentage
of severe anxiety was way higher than that of the present
Fig. 5 Scatter graph of correlation between SGRQ and grades of
dyspnea.
Fig. 6 Scatter graph of correlation between SGRQ and Ham-
ilton Anxiety Scale.
Fig. 7 Scatter graph of correlation between SGRQ and Ham-
ilton Depression Scale.
Fig. 8 Scatter graph of correlation between SGRQ and Speciﬁc
Activity Scale.
Quality of life in with chronic lung diseases 739study: we found only 1.7% of our patients to have severe anx-
iety. Nevertheless, the authors reported that the reason why
the prevalence of anxiety might have been elevated in their
study was that their patients were prescreened by telephone,
and patients lacking any indication of anxiety or depression
were not eligible for study participation, which would presum-
ably result in selection of a population with elevated anxiety
for further screening. The prevalence of anxiety in our COPD
patients was lower than that encountered in IPF or in bronchi-
ectasis. A previous study on patients with chronic lung diseases
reported also a lower prevalence of anxiety in COPD patients
than that in bronchiectasis or asthmatic patients [19].
Not only is anxiety highly common among chronic lung
disease patients but the reverse is also true. The prevalence
of respiratory disease is higher in people with anxiety disorder
than with other psychiatric disease, being as high as 47% [29].Anxiety is associated with greater disability [23] and impaired
functional status [22], speciﬁcally in the areas of general health,
physical roles, emotional roles, social functioning, bodily pain,
mental health function, and vitality [25]. In patients with
chronic lung diseases, anxiety was found to be a predictor of
hospital admission [30] and was associated with longer hospital
stay [31]. In the present study, anxiety score amongst all pa-
tients showed a signiﬁcant correlation with only the age and
the SAS. The Speciﬁc Activity Scale is based on the metabolic
requirements of some types of activities that are often included
in current routine assessments. It represents an acceptable
tradeoff between precision and complexity and has a quite
high reproducibility and validity [32]. Only in the IPF, was
the severity of dyspnea correlated with the anxiety score. How-
ever, previous studies have reported correlations between anx-
iety and dyspnea [31,33]. We found no signiﬁcant correlations
between anxiety score and any of disease severity parameters
notably FVC and FEV1 in any of the studied groups or overall
in all the patients. Furthermore, the arterial oxygen saturation
740 T.S. Morsi et al.was not correlated with the anxiety score except in the bronchi-
ectasis group. Such lack of correlation between FEV1, FVC,
and FEV1/FVC and anxiety was previously reported [31].
However, other studies have found FVC to be correlated with
anxiety score [24]. Although, anxious patients were reported
before to have a shorter 6MWD as compared with non-anx-
ious patients [31], we found no correlation between 6MWD
and anxiety score in any of our studied groups.
In the present study, 58% of the patients with chronic lung
disease had a depression disorder. Again, this prevalence was
higher than most reported ones in patients with chronic lung
disease [22,28,31]. Ryu and colleagues, in their study over
154 patients with chronic lung disease, reported a clinically sig-
niﬁcant level of depression in 51% of their patients [19]. Again,
in the study conducted over 1334 patients with chronic breath-
ing disorders, 70% screened positive for depression. More than
half of those 70% completed a psychological evaluation and
80% of them had a clinically signiﬁcant depression. This latter
was severe in half the cases [1]. In our study, all depression
cases encountered were either mild or much less frequently
moderate. We did not encounter any severe cases of depres-
sion. We found a signiﬁcantly lower prevalence of depression
in bronchiectasis compared to COPD or IPF. A previous study
[19] conducted on patients with chronic lung diseases, reported
a similar prevalence of depression in both COPD and bronchi-
ectasis in 55% of the patients; however, compared to our
results, the depression severity score was higher in COPD
patients.
In persons with chronic lung diseases, although depression
occurs frequently, it is recognized in less than half of depressed
patients [34,35]. Depressed patients with chronic lung disease
have a higher mortality rate, repeated exacerbations, more fre-
quent hospitalizations and longer hospital stay as compared
with non-depressed patients [31]. Those effects of depression
on such patients could be explained by several mechanisms.
Depression induces changes in major immune cell classes
[36,6]. Patients with chronic lung diseases are able to adapt
to chronic symptoms; however the presence of comorbid
depression may interfere with this adaptation process leading
to increases awareness and focus on physical symptoms [37].
Moreover, depressed patients often have lower self-conﬁdence
and a feeling of hopelessness which may entail a suboptimal
disease control due to poor self-care strategies and poor adher-
ence to medications [37,38]. In our study, depression was cor-
related with dyspnea and SAS. Depressed patients were
reported to have a more severe dyspnea and a shorter
6MWD as compared with non-depressed patients [31]. We
found no signiﬁcant correlations between depression and air-
way affection parameters notably FVC and FEV1. However,
a previous study reported that irrespective of the speciﬁc pul-
monary diagnosis, clinically signiﬁcant levels of depression
were more common in patients with airﬂow limitations that al-
tered lung functioning. Lower values of FVC and FEV1 were
more common among chronic lung disease patients with
depression than among those without depression. Moreover,
the value of FEV1 was found to be independently associated
with the development of depression irrespective of individual
diagnosis [19]. Another study found that although depressed
patients had a lower FEV1 and FVC as compared with non-de-
pressed patients; the prevalence of depression did not increase
with disease severity [31]. With the exception of the bronchiec-
tasis group, we found no signiﬁcant correlations betweendepression and the degree of hypoxia. Such observations were
reported before [19].
In the present study, the depression score was signiﬁcantly
correlated with the anxiety score in all three groups and in all
the patients when summed together. Most of our patients who
had depression also had anxiety. The close correlation between
anxiety and depression in patients with chronic lung diseases is
well known; it has been reported in previous studies [19,31,39].
A study which reported on 444 depressed and/or anxious pa-
tients with chronic lung disease, found that 20% of them
met the criteria for depression only, 10% of them met the cri-
teria for anxiety only while 70% met the criteria for both anx-
iety and depression. Moreover, the affection was severe in
more than half of the patients [1]. Their ﬁnding of 61% of pa-
tients with comorbid anxiety and depression is also similar to
community samples of older adults, and to other studies of
geriatric samples [40]. Depression and anxiety in patients with
chronic lung diseases are signiﬁcant comorbid and potentially
modiﬁable disorders. They have direct impact on health and
not just mere consequences or markers of disease severity
[36,6]. Several risk factors for both psychological disorders
are common in such patients, including functional limitations,
feeling less control of life circumstances, and serious life events
[40]. They both have been linked to decreased functional sta-
tus, decreased quality of life and increased mortality. The risk
of missing the appropriate diagnosis and treatment of a con-
current psychiatric complication is evident when patients are
treated in medical clinics [19]. Hurdles to diagnosis and treat-
ment are present at the patient, provider, and system levels. At
the patient level, shame may cause patients with anxiety and
depression to exaggerate somatic symptoms instead of
acknowledging emotional problems. At the provider level,
typecasts and lack of interest or time may be obstacles. At
the system level, the reduced integration of care for mental
health into primary care settings may be a barrier [41].
Therefore, the prevalence of anxiety and depression in pa-
tients with chronic lung diseases is markedly increased com-
pared to the general population [19] and it remains under-
diagnosed. It is disturbing that a mere 30% of patients with
depression or anxiety are being treated, and that only a faintly
higher percentage of those with severe affections are being trea-
ted [1]. The treatment of concurrent psychiatric disorder in such
patients leads to improvement not only in the psychological but
also in the physical state of the patient [19]. Unfortunately,
some data suggest that in spite of treatment, many patients still
meet criteria for depression and/or anxiety affection [1].
HRQL has been acknowledged as a goal for all people
across all life stages by leading health organizations. There is
increasing realization that measures of disease severity alone
are insufﬁcient to determine the patient health state. HRQL
questionnaires allow clinicians to assess directly the impact
of disease on a patient’s daily life. Increased appreciation of
the importance and worth of understanding and measuring
HRQL in chronic respiratory diseases has led to the develop-
ment of several general and disease-speciﬁc HRQL measures
[42]. In our study we used the SGRQ. The SGRQ is a stan-
dardized questionnaire which has been designed to permit
comparative health measurements amongst patient popula-
tions and quantify health changes. It has become one of the
most widely used instruments for assessing HRQL in respira-
tory patients, and has been translated into several languages
[43]. We found the patient SGRQ score in its three components
Quality of life in with chronic lung diseases 741and its total higher than the normal population [43]. That
higher score was encountered in all three groups of patients.
Although the SGRQ is designed in such a way that a score
of zero signiﬁes no quality of life impairment, still persons
who do not suffer from respiratory diseases will hardly ever
score the minimum on all items. Individuals from the general
population express some of the complaints which are pertinent
when measuring HRQL in respiratory patients. Consequently,
the use of the minimum theoretical score (zero) of a speciﬁc
symptom, as a point of reference or a ‘‘true zero’’, may be
unsuitable. Comparison between a patient’s score and zero will
overrate the quality of life affection [43].
In our study male patients had signiﬁcantly higher scores in
SGRQ than female patients. This higher score was encoun-
tered in the three components of the SGRQ and was signiﬁcant
in the symptom and activity scores. Sex has shown a statisti-
cally signiﬁcant effect on the total SGRQ score. Healthy fe-
males had signiﬁcantly higher scores than males for all the
components except symptoms. However, in cases of chronic
lung diseases, it was the males who had a signiﬁcantly higher
score [43]. We also found a signiﬁcant direct correlation be-
tween SGRQ score and the patients’ age: the older the age
the higher the score and the worse the quality of life. Our re-
sults reﬂect the previously recognized effect of age on health-
related quality of life, irrespective of respiratory disease [44].
Moreover, we found the age to be correlated with the activity
and impact component but not the symptom one of the
SGRQ; which is quite understandable. Ferrer and colleagues,
in their work to interpret the quality of life scores from the
SGRQ, found that scores were signiﬁcantly higher among old-
er age groups. They found this ﬁnding not surprising, since
many individuals with respiratory disease from older age
groups may suffer from other chronic conditions [43]. Despite
the postulation that SGRQ measures speciﬁcally the HRQL
impact of respiratory diseases, it has been shown that it may
also reﬂect simultaneously the impact of co-morbidities on
the quality of life of such patients.
The SGRQ score has been shown to be correlated with
measures of disease severity and activity relevant to patients
with chronic lung diseases [42]. We found the SGRQ total
score signiﬁcantly correlated with the duration of the disease
and with the severity of dyspnea. The severity of dyspnea
showed the highest correlation of all variants with the SGRQ,
not only in all patients but also in each of the individual three
groups. Moreover, the severity of dyspnea was signiﬁcantly
and highly correlated with each of the three components of
the SGRQ. A study over patients with chronic lung diseases
who were followed up for 6 months, showed that there were
signiﬁcant differences in the SGRQ total score between pa-
tients who improved and those who deteriorated over the
study period in respect to patients’ symptoms. The SGRQ
Symptoms score not only was it signiﬁcantly higher in patients
who reported having continuous and recurrent symptoms from
chronic lung diseases, but it correlated with the MRC score as
well [42]. The patients’ symptoms score was shown to affect
both the activity and the impact scores but to a lesser degree
than the symptom one [5,42]. Conversely, we found dyspnea
to have greater effect on the activity and impact score than
the symptoms score. This peculiarity was reported before
[42]. However, such ﬁndings should be expected, since the
whole of the scores were designed to reﬂect all domains of
the patient’s health. In practice, patients with chronic lungdiseases seek medical advice for symptoms relief, particularly
dyspnea, as they impair the HRQL of the patients. Most lines
of treatment to such patients would aim at pharmacological
therapy to control symptoms and ameliorate exercise toler-
ance. However, since most chronic lung diseases have no cure,
the main target of treatment should be to improve the patient
HRQL.
We found no signiﬁcant correlation between either the FVC
or FEV1 and SGRQ score. With the exception of the inﬂuence
of the FEV1 on the score in the COPD group, this lack of cor-
relation was encountered all through and in all three groups.
While it is known that decreased FEV1 values are associated
with poorer health status the potency of this correlation is
not always that evident [44]. The relationship between FEV1
and the SGRQ is not established, and even a nonlinear rela-
tionship has been suggested specially in advanced disease
[45]. In previous studies, the correlations between disease-spe-
ciﬁc HRQL measures and spirometry parameters were weak
while there was no signiﬁcant correlation between SGRQ total
score and FEV1 [42]. In our study, the symptom score of the
SGRQ was signiﬁcantly correlated with the FEV1, the activity
component was correlated with the FVC and FEV1 while the
impact component was not correlated with any of the spirom-
etry parameters. Similar to our results, a former study reported
a stronger correlation of the spirometry data notably FEV1
with the activity component than that with the symptom com-
ponent [42]. Again, similar to our results, another study re-
ported inverse correlation between the SGRQ activity score
and the FVC [5]. In a multiple linear regression model in pa-
tients with chronic lung diseases, FEV1 impairment showed
the strongest positive association with HRQL deterioration
[43]. However, in our model, neither the FVC nor the FEV1
showed any predictive value on the SGRQ.
In our study the arterial oxygen saturation was not signiﬁ-
cantly correlated with the SGRQ total score in each of the
three groups and overall in all the patients. Furthermore, it
was signiﬁcantly correlated with only the symptom component
of the SGRQ but not the other two components. On the other
hand, an earlier work found that correlations between PaO2
and the SGRQ scores were stronger than the correlations be-
tween spirometry and the SGRQ; and they were actually sig-
niﬁcant ones [42]. We found the oxygen saturation to have a
predictive value for the SGRQ in the bronchiectasis group only
but not in the other two groups or when all the patients were
included. The activity component of the SGRQ, which mea-
sured the functional status, was the most affected and exhib-
ited some of the highest correlations with disease severity
parameters. The symptom component of the questionnaire
was next in line after the activity component. However, treat-
ment strategies, markers of improvements and follow up are all
often based on symptom components. Yet, limitation of func-
tional status is what matters most to the patients.
In our work, the SAS was signiﬁcantly correlated with
SGRQ overall in all patients and in each of the three groups
separately. Moreover, the SAS was correlated with all three
components of the SGRQ. Together with dyspnea, it was the
parameter that correlated the most with the quality of life
score. It was also one of the four signiﬁcant predictors of
SGRQ. In general, exercise performance is the strongest phys-
iological correlate of the SGRQ total score and its activity
component was most strongly associated with it [42]. On the
other hand, the 6MWD of our patients showed no correlation
742 T.S. Morsi et al.with SGRQ total score except in the COPD group. The
6MWD showed no correlation with any of the three compo-
nents of the SGRQ. However, a previous study reported that
the activity component score inversely correlated with the
6MWD [5].
We found a signiﬁcant direct correlation between SGRQ
score and both HAMA and HAMD. Moreover, the HAMA
and HAMD were both signiﬁcantly correlated separately with
each of the three components of the SGRQ. However, the im-
pact component had the strongest correlation in comparison
with the symptom and activity components. In cases of chronic
lung diseases, depressed and anxious patients had a worse
quality of life compared to patients without psychological dis-
orders [5,31]. Wilson and colleagues [42] found results similar
to ours. The SGRQ total score was signiﬁcantly correlated
with both the anxiety and depression scores; with the depres-
sion having the strongest correlation. They also reported that
depression was signiﬁcantly correlated with all three compo-
nents of the SGRQ, while anxiety with the impact component
only. The various scores for general health, fatigue and mood
state generally correlate better with the impact component
than other two components. The impact section does include
some items expected to transmit feelings of anxiety and depres-
sion, such as social stigmatization, panic and being in control
of one’s health, it would be expected that this component
would be more strongly related to psychological features of
lung disease than the other components of the SGRQ [42].
On our linear regression analysis, the HAMD was a signiﬁcant
predictor of the SGRQ. The HAMA, although was not found
to be a predictor of the SGRQ overall the patients, it was
found to be a signiﬁcant predictor in two groups: IPF and
bronchiectasis ones.
We believe this study has certain limitations. We did not as-
sess the patients’ standard of living, economic conditions, edu-
cational level and family issues, all of which may have a weight
on psychological distresses and quality of life. From a clinical
perspective, these variables are difﬁcult to measure or quantify
specially in an outpatient setting of a pulmonary clinical prac-
tice. Future studies are needed to conﬁrm our ﬁndings.
In conclusion, patients with chronic respiratory diseases are
at increased risk for depression and anxiety; both of which re-
main under-diagnosed. Routine assessment and screening for
anxiety and depression in all patients with chronic lung dis-
eases should be considered. The SGRQ is a valid measure
for quality of life in patients with chronic lung diseases that ap-
pear to be sensitive in distinguishing different levels of health
impairment in such patients. Body mass index, severity of
dyspnea, Speciﬁc Activity Scale and Hamilton Depression
Scale were found to be independent predictors for quality of
life in patients with chronic lung diseases.
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